Cargando…

Refining pancreatic ductal adenocarcinoma molecular subtype and precision therapeutics with single-nucleus RNA-seq

Detalles Bibliográficos
Autor principal:	He, Lishu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	MedViews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371831/ https://www.ncbi.nlm.nih.gov/pubmed/34404394 http://dx.doi.org/10.1186/s12916-021-02052-y

Ejemplares similares

What further should be done to control COVID-19 outbreaks in addition to cases isolation and contact tracing measures?
por: He, Zhenjian
Publicado: (2020)

Epidemiological models are important tools for guiding COVID-19 interventions
por: Thompson, Robin N.
Publicado: (2020)

Mendelian randomization—a powerful tool to study the causal effects of atrial fibrillation on loss of brain volume
por: Andreasen, Laura
Publicado: (2021)

What neurological and psychiatric effects does COVID-19 have on its survivors?
por: Mentis, Alexios-Fotios A.
Publicado: (2021)

Mast cells in pancreatic ductal adenocarcinoma
por: Chang, David Z.
Publicado: (2012)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Efficacy of 18F-FDG PET/CT in investigation of elevated CEA without known primary malignancy
por: Wong, Simon Sin-man, et al.
Publicado: (2016)

Occupational Cutaneous Burn
por: Idowu Obafemi, Adebisi
Publicado: (2017)

A Brownish Skin Lesion on the Upper Neck
por: Memarazad, Sepehr
Publicado: (2016)

An Unforeseen Hazard of Masks Being in Vogue
por: Sinha, Anwita, et al.
Publicado: (2020)

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
por: Espiau-Romera, Pilar, et al.
Publicado: (2020)

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma
por: Janky, Rekin’s, et al.
Publicado: (2016)

Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
por: Collisson, Eric A., et al.
Publicado: (2011)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Recent advances in precision medicine for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma
por: Fan, Yuhui, et al.
Publicado: (2020)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
por: de Santiago, Ines, et al.
Publicado: (2019)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
por: Ottenhof, Niki A., et al.
Publicado: (2011)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes
por: Zhao, Lan, et al.
Publicado: (2018)

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
por: Yu, Yiqi, et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
por: Loi, Sherene
Publicado: (2013)

Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma
por: Wei, Ran, et al.
Publicado: (2022)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
por: Kaissis, Georgios A., et al.
Publicado: (2020)

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
por: Taherian, Mehran, et al.
Publicado: (2022)

Molecular Subtyping and Precision Medicine for Pancreatic Cancer
por: Froeling, Fieke E. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oeam3oeijam5grmptn56qmvujs